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conditions, particularly in the nervous system.9–11
Many human tumors constitutively express IDO.12 It has been
shown that an increased level of IDO expression in tumor cells is
correlated with poor prognosis for survival in cancer.13,14 This led
to the hypothesis that IDO inhibition might enhance the efﬁcacy
of cancer treatments. Indeed, results from in vitro and in vivo stud-
ies have suggested an improvement of the efﬁcacy of therapeutic
70vaccination or chemotherapy by concomitant administration of
an IDO inhibitor thus highlighting IDO as an attractive tar-
get.12,13,15–17
Q
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1. Introduction
Immunotherapy is a promising novel strategy for cance
treatment. It consists of therapeutic vaccination of cancer patient
in order to stimulate their (natural) immune system against cance
cells. This approach, however, showed limited efﬁcacy in vivo. In
deed, cancer cells are able to develop enzymatic mechanism
allowing tumors to resist or escape immune rejection. Among th
enzymes involved, the indoleamine 2,3-dioxygenase (IDO; E
1.13.11.52) represents a crucial actor.1,2
IDO is a 45 kDa monomeric extrahepatic cytosolic hem
dioxygenase which catalyzes the initial and rate-limiting step i
the catabolism of the essential amino acid tryptophan (Trp) alon
the kynurenine pathway, the de novo biosynthetic route leadin
1
Contents lists av
Bioorganic & M
journal homepage: wwto nicotinamide adenine dinucleotide (NAD).3,4 IDO is a more
promiscuous enzyme than the catalytically related hepatic enzyme
tryptophan 2,3-dioxygenase (TDO; EC 1.13.11.11). Apart from both
tryptophan enantiomers, IDO substrates are indoleamines such as
serotonin, melatonin, and tryptamine.5 In order for IDO to be cata-
lytically active, it is essential to maintain the heme iron ion in the
ferrous (Fe2+) state. As the enzyme is susceptible to autoxidation, a
reductant is necessary for preserving the enzymatic activity.
Cytochrome b5 has been demonstrated to play this role in vivo.6,7
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um
se (IDO) is a heme dioxygenase which has been shown to be involved in th
e of diseases such as cancer. The synthesis and structure–activity relationship
inhibitors based on the indol-2-yl ethanone scaffold is described. In vitro an
ave been evaluated, leading to compounds with IC50 values in the micromola
ction of small substituents in the 5- and 6-positions of the indole ring, indo
ns of the aromatic side chain are all well tolerated. An iron coordinating grou
te for biological activity, thus corroborating the virtual screening results.
 2010 Published by Elsevier Lt
By depleting Trp locally, IDO blocks the proliferation of T lym
phocytes, which are sensitive to Trp shortage.8 The downstream
catabolites of the kynurenine pathway exacerbate this immuno
suppressive effect1 and are also involved in other pathologica
able at ScienceDirect
dicinal Chemistry
.e lsevier .com/locate /bmcUntil recently, the best known IDO inhibitors18 displayed
afﬁnities in the micromolar range and comprised mainly Trp
derivatives such as 1-methyltryptophan (1MT)19 (Ki = 37 lM) or
b-carbolines (Ki 0.12 mM).20 Other indole-based IDO inhibitors,
such as brassinin21,22 and methylthiohydantoin-tryptophan
(MTH-Trp)13 have beendescribed. The best inhibitor of the brassinin
class has a Ki of 12 lM but is not Lipinski-compliant due to high
80hydrophobicity.22
In 2006, potent IDO inhibitors were isolated from marine inver-
tebrate extracts,23,24 leading to two new series of uncompetitive
nanomolar inhibitors.26,27 However, some of the most active
compounds of the original series revealed to be inactive in a
m. (2010), doi:10.1016/j.bmc.2010.12.032
yeast-based cellular assay, suggesting poor cell penetration.7 This
test nevertheless provided two new micromolar inhibitors with
unknown modes of action.
In 1989, 4-phenylimidazole (PIM) was identiﬁed as a modestly
potent IDO inhibitor.4,19 Despite the uncompetitive inhibition
90 kinetics, the authors showed through spectroscopic studies that
PIM binds into the active site of IDO. Moreover, they discovered
a preferred binding of PIM to the inactive ferric (Fe3+) form of the
enzyme, which may explain this apparent discrepancy. The ﬁrst
crystal structure of human IDO complexed with the inhibitor
reported later25 conﬁrmed the binding of PIM in the active site. A
recently undertaken structure-based study26 of PIM-derived mole-
cules prompted by Sugimoto’s work conﬁrmed the antecedent
ﬁndings while providing access to novel inhibitors with low micro-
molar potencies.
100 Recent developments in the ﬁeld include hypoxic-neoplastic
cells-targeting 1MT-tirapazamine hybrids,27 novel inhibitors ob-
tained from marine sediments (IC50  2 lM),28 potent competitive
inhibitors including a hydroxyamidine chelating motif (IC50 values
down to 60 nM),29 strong inhibition by modiﬁcation of cysteine
residues by ebselen,30 sub-micromolar S-benzylisothiourea-based
inhibitors active in cells,31 various potent inhibitors (IC50 values
down to 0.2 lM) discovered by a combination of a docking-based
pharmacophore model development and fragment-based drug de-
sign (FBDD).32
110 Despite all these efforts, modestly potent 1MT (Ki = 34 lM)19
remains the only compound to have been passed into clinical trials
as an IDO inhibitor so far.33 This prompted us to search for new
scaffolds that could be further optimized with the objective of
identifying potent and selective IDO inhibitors. Brieﬂy, a collection
of 62,000 structures was downloaded from the ZINC website
using Lipinski-style rules for fragments (molecular weight  250,
Log P  2.5, number of rotatable bonds  5).34 These compounds
were docked inside the IDO active site and ranked according to
their best potential binding. From the 39 compounds that were se-
120 lected, bought and assayed on IDO, six derivatives displayed an
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groups to explain substrate binding as well as interaction of
1MT. In this position, the 3-pyridyl group is projected towards
the entrance of the active site and is stabilized in the aromatic
Pocket B through T-shape interactions with Phe163 and Phe226
140(Fig. 1).
Our structural modiﬁcations of 7a were focused on exploiting
three binding interactions with IDO: (1) the interior of the active
site, in particular interactions with C129 and S167 in Pocket A;
(2) the active site entrance region (Pocket B) occupied by the
N-cyclohexyl-2-aminoethanesulfonic acid (CHES) buffer molecule
in a crystal structure;25 (3) the heme iron binding group. According
to the binding orientation of 7awe hoped to achieve interactions in
the interior region of the active site (Pocket A) by introducing sub-
stituents on the indole ring. The substituents were chosen with a
150view to balance on one side the lipophilic character of this Pocket
introducing groups such as ﬂuorine, bromine, chlorine, methyl;
and, on the other side the possibility of forming H-bond interac-
tions with speciﬁc amino acids with such substituents as hydroxyl,
methoxy, nitro, or triﬂuoromethoxy. The interaction within Pocket
B would be probed by replacement of the 3-pyridyl group of 7a
with other (hetero)aromatics. The heme iron binding interaction
would be explored by replacement of the ethanone moiety with
other linkers between the indole and the aromatic side chain.
2. Chemistry
160Initial efforts to prepare analogues of compound 7a included at-
tempts to react indole-2-acyl chlorides (Scheme 1, 3, R00 = Cl) with
reagents derived from 3-bromomethylpyridine hydrobromide un-
der various conditions.36–38 In fact, all of these approaches revealed
to be unsatisfactory, the main difﬁculty likely being the intrinsic
instability of the in situ generated free base 3-bromomethylpyri-
dine which readily oligomerizes.39 The only strategy allowing ac-
cess to 7a analogues was the approach originally developed by
Sundberg et al., as outlined in Scheme 1. This method involves
the LDA effected deprotonation of alkylarene 1 followed by
170qu
ca
slo
up
targeted compounds.
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Figure 1. View of the lead compound 7a inside the IDO binding cleft. (Picture made
with Pymol34).
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Plhibitory potency >30% at a concentration of 100 lM. Among
ese, compound 7a, characterized by an indole nucleus substi-
ted in the 2-position by a 2-pyridinyl-ethanone function, was
r best hit (IDO IC50 65 lM), with an inhibitory potency in the
me range as the reference compound 1MT. (Table 1). Herein
report the synthesis and structure–activity study of compound
.
An initial docking study of 7a within the IDO binding cleft was
rformed by means of the automated GOLD program35 and re-
aled essential features stabilizing 7a in the IDO binding cleft
d particularly that (i) the oxygen atom of the ketone function,
ing situated 2 Å above the plane of the heme, coordinates to
e heme iron, (ii) the indole ring is found to be stabilized in the
-called lipophilic A-pocket of IDO.32 Indeed, this stabilization of
e indole residue in Pocket A was already suggested by other
le 1
ibition of IDO activity by 1MT and 7a identiﬁed using VS
Compound Structure IC50 (lM)
1MT
N
NH2
O
OH
Me
100 ± 20
7a
H
N
O
N 65 ± 7ease cite this article in press as: Dolušic´, E.; et al. Bioorg. Med. Chem. (2enching of the in situ generated carbanion with a reactive indole
rbonyl compound (3 and 6) at 0 C. Stirring overnight while
wly attaining room temperature followed by aqueous work-
, chromatographic puriﬁcation and crystallization provided the010), doi:10.1016/j.bmc.2010.12.032
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The catalytic hydrogenation of 7a afforded the hydroxyl
derivative 18 (Scheme 2). Compound 19 bearing an ethylene linker
between the two aromatic rings was prepared from 7a by a
itions: (i) LDA, THF/hexanes, 78–0 C, 1 h; (ii) SOCl2, D, 15 min; (iii) THF/hexanes, 0 C to
(lW), 5 min; (vi) MeI, K2CO3, DMF, 80 C, 16 h to 5 days; (vii) AlCl3, CH2Cl2, 0 C to rt, 24 h;
n; (x) PhB(OH)2, Pd(PPh3)4, K2CO3, EtOH/toluene 1:1, D, 20 h.
E. Dolušic´ et al. / Bioorg. Med. Chem. xxx (2010) xxx–xxx 3
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22 December 2010Accordingly, most of the compounds 7 as well as 8a, 9a, 10
and 11awere prepared from indole esters (3, R00 = OMe, OEt) or acy
chlorides (3, R00 = Cl) when these starting material were commer
cially available. Otherwise, the necessary indole acyl chloride
was prepared by reaction of the commercially available indole-2
carboxylic acid 2 in reﬂuxing thionyl chloride. Non-commerciall
available indole esters 3 were made using the Hemetsberger–Kni
tel procedure starting from the corresponding a-azidocinnamate
5, which were in turn made by condensation of the substitute
benzaldehydes 4 with ethyl azidoacetate under Knoevenagel con
ditions (Scheme 1).40,41 It should be noted that compound 11
(Scheme 1) was prepared in 37% yield using commercial Grignar
reagent in lieu of the LDA procedure. Moreover, during the cours
of this reaction, the tertiary alcohol 16 (inactive in the biologica
tests; data not shown) was also isolated in 17% yield.
Palladium catalyzed reductions were used to convert benzy
oxy-substituted 2-ketoindoles 7n and 7r to their debenzylate
counterparts 7o and 7s, respectively. Bis-alcohol 17 was als
Scheme 1. General synthetic scheme for indol-2-yl ethanones. Reagents and cond
rt, 16–24 h; (iv) N3CH2CO2Et, NaOEt, EtOH, 10–4 C, 1.5–20 h; (v) hexane, 200 C
(viii) HCO2NH4, Pd black, MeOH, rt, 1 h; (ix) H2 (1 atm), 3% Pd/C, EtOH, rt, 45 miisolated as a byproduct during the catalytic reduction of 7n. The
5-phenylindole derivative 7l was prepared from the corresponding
5-bromo analogue 7h by a Suzuki cross-coupling with
phenylboronic acid (Scheme 1). Finally, after initial unsuccessful
attempts to demethylate 8dwith boron tribromide (which seemed
to cause product decomposition), the 4-hydroxyindole 8e was ob-
tained by reaction of 8d with aluminum trichloride in
dichloromethane.
For the synthesis of theN-methylated analogue 12a, the required
N-methylated indole ester 6 was synthesized by dimethylation of
N-unsubstituted indole-2-carboxylic acid 2 (Scheme 1).42
d
2,
v)
Please cite this article in press as: Dolušic´, E.; et al. Bioorg. Med. CheScheme 2. Synthesis of compounds bearing different linker groups. Reagents an
conditions: (i) HCO2NH4, Pd black, MeOH, rt, 3 days; (ii) H2NNH2, KOH, (CH2OH)
lW, 1 h then aq NH4Cl; (iii) NH2OHHCl, pyridine, EtOH, lW (120 C), 30 min; (i
SOCl2, D, 15 min then 3-aminopyridine, DIPEA, THF, 0 C?rt, 30 min.m. (2010), doi:10.1016/j.bmc.2010.12.032
Wolff–Kishner reduction. Oxime 20 was obtained by reacting
ketone 7a with hydroxylamine. Finally, amide 21 was made from
acid 2 by reaction with thionyl chloride followed by nucleophilic
210 substitution with 3-aminopyridine (Scheme 2).
The structure of all compounds was conﬁrmed by means of 1H,
13C and (where applicable) 19F NMR, LC–MS, and elemental analy-
sis (see Section 5). In addition, single crystal X-ray diffraction was
used to corroborate the structures obtained in these series. The
molecular structures of compounds 7a and 7m with displacement
ellipsoids drawn at the 50% probability levels are depicted in
Figure 2. It should be noted that for 7m thermal agitation of the
triﬂuoromethoxy side chain led to large displacement ellipsoids
for the ﬂuorine atoms.
220 3. Results
3.1. IDO inhibition through interactions in the interior of the
active site (Pocket A)
Detailed analysis of the binding conformation of 7a inside the
IDO binding cleft suggests that introduction of small substituents
around the indole scaffold could be beneﬁcial for IDO inhibition.
Starting from our hit 7a (IC50 = 65 lM), we ﬁrst explored the
inﬂuence of substitution around the indole ring. From Table 2 it
can be observed that introduction of substituents in the 3- (7b),
4- (7c–e), and 7-position (7q) does not generally afford more
230 po
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th
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Table 2
IDO inhibitory potency of compounds 7a–u, 12a
N
O
R N2
34
5
6
7 R1
Compound R R1 IDO IC50 (lM) IDO cell assay
inhibition % @ 20 lM
7a H H 65 ± 7 13
7b 3-Br H NI NI*
7c 4-F H 153 ± 23 12
7d 4-MeO H 58 ± 5 NI
7e 4-OH H 83 ± 18 NI
7f 5-F H 36.0 ± 0.1 24
7g 5-Cl H 24.6 ± 0.1 24
7h 5-Br H 18 ± 1 NI
7i 5-Me H 87 ± 11 21
7j 5-OMe H 49 ± 1 NT
7k 5-NO2 H NI NI
7l 5-Ph H 96 ± 1 NI
7m 5-CF3O H 13.1 ± 0.1 12
7o 5-OH H 37 ± 3 NI
7p 6-F H 43 ± 7 NI
7q 7-MeO H 82 ± 5 6
7r 4-BnO, 5-MeO H NI NI
7s 4-OH, 5-MeO H 63 ± 3 11
7t 4,6-DiCl H 139 ± 12 NI
7u 4,6-DiMeO H 45 ± 8 Toxic
12a H Me 34 ± 2 NI
⁄⁄ N
* N
Tab
IDO
* N
Q3
4 E. Dolušic´ et al. / Bioorg. Med. Chem. xxx (2010) xxx–xxx
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Pltent compounds than the hit 7a. Substitutions in the 5- and
positions are well tolerated and more potent compounds are
tained. Particularly, introducing a triﬂuoromethoxy group on
e 5-position of the indole ring led to a ﬁvefold improvement in
e IDO inhibitory potency. Regarding the disubstitution, introduc-
ns of substituents in the 4,5- or the 4,6-positions do not drasti-
lly affect IDO inhibition. Finally, N-methylation of the indole
cleus seems to be tolerated as 12a is in vitro twofold more po-
nt than parent compound 7a.
. IDO inhibition through interactions with Pocket B of the
tive site
We next explored the inﬂuence of modifying the fragment
teracting with Pocket B of the IDO active site. From Table 3, it
n be observed that introductions of an unsubstituted phenyl
1a), a 2-pyridyl (8a) or a 2-pyrazinyl group (10a) in lieu of the
pyridyl moiety of 7a slightly improve the IDO inhibitory potency
50’s of 29, 37, and 26 lM, respectively). On the contrary, intro-
ction of a 4-pyridyl moiety (9a) afforded an inactive compound.
. IDO inhibition through interaction with the heme iron
nding group
Finally we appraised the importance of the ketone moiety of
mpound 7a in establishing an interaction with the heme iron. In-
ed, reduction of this group (18) or its removal altogether (19) led
inactive compounds thus conﬁrming the requirement for an iron
in
th
sta
as
an
2604.
in
in
waordinating group (Table 4). Oxime 20 is endowed with an in vivo
ure 2. The molecular structures of (a) 7a and (b) 7m. Displacement ellipsoids
drawn at the 50% probability levels. (Pictures made with MERCURY2.3).ease cite this article in press as: Dolušic´, E.; et al. Bioorg. Med. Chem. (2hibitory potency similar to that of ketone 7a but surprisingly,
is compound is not active in vitro. This might result from a poor
bility of the oxime moiety in the experimental conditions of the
say. Methylating the ethanone link (7v) or its replacement with
amide (21) afforded less potent compounds.
Discussion and conclusion
About 30 original compounds were synthesized around the
dol-2-yl ethanone scaffold and their in vivo and in vitro
hibitory potency against indoleamine 2,3-dioxygenase (IDO)
s evaluated. Starting from the hit (1H-indol-2-yl)-2-pyridin-3-
T = not tested.
I = no inhibition.
le 3
inhibitory potency of compounds 7a–11a
H
N
O
Ar
Compound Ar IDO IC50 (lM) IDO cell assay
inhibition % @ 20 lM
7a
N
*
65 ± 7 13
8a
N
*
37 ± 15 10
9a
N
*
NI NI*
10a N
N
*
26.2 ± 0.2 NI
11a
*
29 ± 26 NI
I = no inhibition.010), doi:10.1016/j.bmc.2010.12.032
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22 December 2010yl-ethanone (7a) identiﬁed through a virtual screening procedur
and possessing an IC50 of 65 lM in the in vitro test, a ﬁvefol
improvement in potency (IC50 = 13 lM) could be achieved b
introducing a triﬂuoromethoxy group in the 5-position of the in
dole nucleus. Most small substituents around the indole moiet
led to compounds of roughly equivalent potency, indicating room
for further modiﬁcations but also a probable lack of close interac
tions of the inhibitor molecules with the IDO Pocket A interior a
described by Rohrig et al.32 A similar generalization can be applie
to the other aromatic moiety and its putative interactions wit
Pocket B of the IDO. Altogether, it seems no strong H-bond interac
tions with any of the hydrogen bonding residues in the IDO activ
site could be established. The presence of an iron chelating grou
seems to be of crucial importance, since its deletion leads to los
of potency.
A number of compounds investigated here possess a moderat
in vivo activity. The compounds 7f and 7g (with small haloge
atoms in the 5-position of the indole moiety) are both endowe
with 24% IDO inhibition at a 20 lM concentration in the cellula
assay, which indicates reasonable cell penetration. A very simila
value was obtained for oxime 20.
In summary, a novel series of compounds with a moderat
inhibitory activity against IDO has been identiﬁed. Both in vitr
and in vivo assays show promising results. Further modiﬁcation
aiming to achieve more favorable interactions with the enzyme ac
tive site are in due course.
5. Experimental part
5.1. Chemistry
5.1.1. General experimental procedures
Chemicals were purchased from commercial suppliers (Acro
Sigma–Aldrich, Maybridge, Apollo) and used without furthe
puriﬁcation. All solvents were used as purchased from Acro
Sigma–Aldrich, Fisher Scientiﬁc and Biosolve. All reactions wer
performed under an inert argon (Alphagaz 2) atmosphere, unles
stated otherwise. Melting points were determined in open capillar
Table 4
IDO inhibitory potency of compounds 7a, 7v, 18–21
Compound Structure
7a N
H
O
N
7v N
H N
O
Me
18 N
H
OH
N
19 N
H N
20 N
H N
NOH
21 N
H
HN
N
O
NI = no inhibition.Please cite this article in press as: Dolušic´, E.; et al. Bioorg. Med. Cheies on a Büchi B-540 capillary melting point apparatus and ar
uncorrected.
Thin layer chromatography (TLC) was performed on silica ge
plates (60F254, 0.2 mm thick, Merck) eluting with gradients of ethy
acetate in cyclohexane. The spots were visualized by ultraviole
light (wavelengths 254 and 366 nm).
1H NMR spectra were recorded in DMSO-d6 solutions on a Jeo
JNM EX 400 machine at 400 MHz with tetramethylsilane (TMS
as internal standard. 13C and 19F NMR spectra were recorded o
the same machine in DMSO-d6 solutions at 100 MHz an
376.2 MHz, respectively. Chemical shifts (d) are reported in ppm
downﬁeld from TMS.
Elemental analyses (C, H, N, S) were performed on a Therm
Finnigan FlashEA 1112 apparatus.
Analytical LC–MS analyses were performed on an Agilent 110
Series LC–MSD Trap system using UV detection at 254 and 366 nm
MS data were recorded using electrospray ionization (ESI) opera
ing in positive mode. The following two methods were applied
method 1: injection of 10 ll of a 20 lg/mL acetonitrile solutio
onto a C18-3.5 lm Zorbax SB column (100  3 mm); separatio
using a gradient (ﬂow rate: 0.5 mL/min) of acetonitrile in acet
acid 0.1% (v/v) in water: 5–95% acetonitrile during 5 min, holdin
for 3 min, then reversing to 5% acetonitrile during 0.1 min an
holding for an additional 5.4 min. Method 2: injection of 10 ll o
a 2 lg/mL acetonitrile solution onto a C18-5 lm Agilent LiChro
spher 100 column (250  4 mm); separation using a gradient (ﬂow
rate: 1.0 mL/min) of acetonitrile in acetic acid 0.1% (v/v) in wate
20–80% acetonitrile during 20 min, holding for 20 min, the
reversing to 20% acetonitrile during 0.1 min and holding for a
additional 5 min.
Automated ﬂash chromatography was performed on th
Biotage AB (Uppsala, Sweden) SP1 system equipped with pre
packed ﬂash KP-Sil silica cartridges eluting with gradients of ethy
acetate in cyclohexane. The peaks were detected by UV absorptio
at 254 and 320 nm.
The yields refer to combined yields of chromatographically an
spectroscopically pure (>95%) compounds and the crops obtaine
by evaporation of mother liquors. All new compounds were deter
mined to be >95% pure by LC–MS and NMR.
IDO IC50 (lM) IDO cell assay inhibition % @ 20 lM
65 ± 7 13
141 ± 4 NI
NI NI
NI NI
19.4% @ 100 lM 25
94 ± 2 NIm. (2010), doi:10.1016/j.bmc.2010.12.032
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PlThe microwave-assisted syntheses were carried out in an Initi-
or 16 single-mode microwave instrument producing controlled
adiation at 2.450 GHz (Biotage AB). Reaction times refer to hold
es at the temperatures indicated, not to total irradiation times.
e temperature was measured with an IR sensor on the outside of
e reaction vessel.
.2. Methods for preparation of indolic intermediates (3 and
.2.1. Indole-2-acyl chlorides (3, R00 = Cl). Commercial indole-
carboxylic acid was dissolved in thionyl chloride (1.5 mL/
mol) and the suspension was boiled for 15 min, during which
e typically a dark green solution was formed. Excess thionyl
loride was removed under reduced pressure and the solid resi-
e was suspended in toluene and the suspension was evaporated
dryness (toluene treatment was repeated three times). The
een-grayish solid residues were used without further
riﬁcation.
.2.2. Indolic esters by Hemetsberger–Knittel synthesis (3,
= OEt)40,41. Sodium (4.0 equiv) was dissolved in absolute etha-
l (0.5 mL/mmol) and the solution was cooled to 10 C in an ice/
etone bath. A corresponding benzaldehyde (1.0 equiv) was dis-
lved in a commercial 25% solution of ethyl azidoacetate in etha-
l (2.1 g per mmol of starting benzaldehyde, 4.0 equiv) and this
lution was added dropwise to the sodium ethoxide solution dur-
g 30 min while the bath temperature was kept at 10 C. The
action mixtures typically turned into bright yellow suspensions.
e stirring was continued until TLC (developing with 15% EtOAc
cyclohexane) indicated completion or the reaction (1.5–2.5 h).
the reaction required more than 1.5 h, the temperature was al-
ed to rise to 0 C. In one case (5r), the reaction had to be run
ernight. The mixtures were partitioned between ethyl acetate
d water. The aqueous phase was extracted twice with ethyl ace-
te and the organic layers were pooled, washed with brine, dried
er magnesium sulfate, and concentrated under reduced pressure
provide crude azidoacrylic esters (5) as yellow to orange oils or
uids in a 46–100% yield. These products were suspended in n-
xane (6–9 mL/mmol of crude azidoacrylic ester) and subjected
microwave heating at 200 C for 5 min (P = 100–140W,
12–13 bar). The resulting residues were taken into ethyl acetate
d evaporated with silica gel. The corresponding indolic esters 3
ields 19–93%) were puriﬁed by chromatography. In one case, a
ixture of isomers was obtained. 2-Azido-3-(3-methoxyphenyl)-
rylic acid ethyl ester gave 5-methoxy-1H-indole-2-carboxylic
id ethyl ester (3j) and 7-methoxy-1H-indole-2-carboxylic acid
hyl ester (3q) in a 1:1 ratio (each in a 47% yield).
.2.3. N-Methylated indolic ester; methyl 1-methyl-1H-indole-
carboxylate (6). Prepared according to a literature procedure.42
ethyl iodide (5.0 mL, 80.0 mmol) was added to a stirred suspen-
n of anhydrous potassium carbonate (6.3 g, 45.6 mol) and 1H-
dole-2-carboxylic acid (2; 5.3 mmol) in dry DMF (6 mL) and the
ixture was stirred at 80 C until the reaction was complete as
dicated by TLC and/or LC–MS (3–5 days). Upon cooling to room
mperature, the suspension was partitioned between ethyl ace-
te and water. The aqueous phase was extracted with ethyl ace-
te and the combined organic layers were dried over MgSO4,
ncentrated under reduced pressure and dried to yield the desired
methylated indole ester (6) as a beige solid in a 96–99% yield.
.3. General synthetic procedure for 1-(1H-indol-2-yl)-2-aryl-
tones (7–10, 12)43
An oven-dried ﬂask was purged with argon while hot, then
owed to cool down to room temperature under argon and
arged with dry THF (2 mL/mmol of starting indole 3/6) and diiso-
(1
NM
ease cite this article in press as: Dolušic´, E.; et al. Bioorg. Med. Chem. (2opylamine (4.0 equiv). The solution was cooled to78 C in a dry
/isopropanol bath and n-butyl lithium, 1.6 M solution in
xanes (4.0 equiv), was added to give a bright yellow solution.
e mixture was stirred for 30 min below 60 C whereupon a
lution of picoline or another appropriate reagent with an ioniz-
le methyl(ene) group (4.0 equiv) in THF (2 mL/mmol of starting
dole 3 or 6) was added to give a yellow to red colored mixture.
ring a further 30 min, the bath temperature was allowed to rise
approx. 0 C during which time the reaction mixture became a
llow to red suspension. The temperature was then kept at 0 C
sing an ice/water bath) for an additional 30 min. At this point,
solution of the indole-2-carbonyl compound 3/6 (1.0 equiv) in
F (4 mL/mmol) was added dropwise over the ﬂask wall. The
action mixture darkened (dark purple to dark brown color in
ost cases) and was then allowed to attain room temperature
ernight. At 18 h (unless otherwise stated) after the addition of
e indole component, the reaction was quenched with saturated
ueous ammonium chloride solution (10 mL/mmol of starting
mpound 3/6) and stirred for several minutes. Upon partition be-
een ethyl acetate and water, the aqueous phase was extracted
ice with dichloromethane and the combined organic layers were
ied over MgSO4. The title products were puriﬁed by chromatog-
phy (the products typically eluted with 70–80% of ethyl acetate).
e products were then precipitated by concentration of the
oled column fractions combined with the addition of cyclohex-
e. The precipitates formed were ﬁltered off, washed twice with
clohexane and dried at 40 C in vacuo to yield analytically pure
mples. The following compounds were prepared in this way:
.3.1. 1-(1H-Indol-2-yl)-2-pyridin-3-yl-ethanone (7a)43–45.
epared from commercial 1H-indole-2-carboxylic acid ethyl ester
(986 mg, 5.05 mmol) and 3-picoline. Yellowish solid (699 mg,
%), mp 177–180 C. LC–MS Rt 5.2 min (method 1), 7.0 min
ethod 2); m/z [MH+] 237. 1H NMR d 11.76 (1H, br s, indole-
), 8.53 (1H, d, J = 1.7 Hz, ArH), 8.43 (1H, dd, J = 4.8, 1.7 Hz,
H), 7.71 (1H, d, J = 7.8 Hz, ArH), 7.69 (1H, d, J = 7.8 Hz, ArH),
6 (1H, d, J = 1.8 Hz, ArH), 7.41 (1H, d, J = 8.2 Hz, ArH), 7.33
H, dd, J = 7.8, 4.8 Hz, ArH), 7.26 (1H, t, J = 7.6 Hz, ArH), 7.06
H, t, J = 7.6 Hz, ArH), 4.36 (2H, s, CH2). 13C NMR d 190.1 (C@O),
1.1 (ArC), 148.3 (ArC), 138.6 (ArC), 137.8 (ArC), 135.4 (ArC),
1.6 (ArC), 127.4 (ArC), 126.2 (ArC), 124.0 (ArC), 123.3 (ArC),
0.9 (ArC), 113.3 (ArC), 110.7 (ArC), 42.0 (CH2). Anal. Calcd for
5H12N2O: C, 76.25; H, 5.12; N, 11.86. Found: C, 76.16; H, 5.13;
11.87.
.3.2. 1-(3-Bromo-1H-indol-2-yl)-2-pyridin-3-yl-ethanone (7b).
epared from commercial 3-bromo-1H-indole-2-carboxylic acid
67 mg, 1.09 mmol) and 3-picoline via corresponding acyl chlo-
e 3b (method A). Bright yellow solid (100 mg, 29%), mp 194–
5 C (dec). LC–MS Rt 6.0 min (method 1), 12.8 min (method 2);
z [MH+] 315; 317. 1H NMR d 12.19 (1H, br s, indole-H1), 8.49
H, d, J = 1.8 Hz, ArH), 8.45 (1H, dd, J = 4.8 Hz, 1.6, ArH), 7.69
H, d, J = 7.8 Hz, ArH), 7.57 (1H, d, J = 8.0 Hz, ArH), 7.49 (1H, d,
8.2 Hz, ArH), 7.38–7.33 (2H, overlapped, 2 ArH), 7.19 (1H, t,
7.6 Hz, ArH), 4.53 (2H, s, CH2). 13C NMR d 189.3 (C@O), 151.4
rC), 148.4 (ArC), 138.2 (ArC), 136.5 (ArC), 132.1 (ArC), 130.8
rC), 127.6 (ArC), 127.3 (ArC), 123.9 (ArC), 122.0 (ArC), 121.2
rC), 113.7 (ArC), 96.5 (ArC), 44.4 (CH2). Anal. Calcd for
5H11BrN2O: C, 57.16; H, 3.52; N, 8.89. Found: C, 58.26; H, 3.57;
8.48.
.3.3. 1-(4-Fluoro-1H-indol-2-yl)-2-pyridin-3-yl-ethanone (7c).
epared from 4-ﬂuoro-1H-indole-2-carboxylic acid ethyl ester 3c
ethod B; 184 mg, 0.89 mmol) and 3-picoline. Yellow half-solid
5 mg, 7%). LC–MS Rt 5.4 min (method 1); m/z [MH+] 255. 1H
R d 12.10 (1H, br s, indole-H1), 8.53 (1H, br s, ArH), 8.43 (1H,
010), doi:10.1016/j.bmc.2010.12.032
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22 December 2010d, J = 4.1 Hz, ArH), 7.73–7.65 (2H, overlapped, 2 ArH), 7.33 (1H, dd
J = 7.2, 5.1 Hz, ArH), 7.24 (2H, overlapped, 2 ArH), 6.85 (1H, m
ArH), 4.40 (2H, s, CH2). 13C NMR d 190.2 (C@O), 167.5 (ArC
149.8 (d, JCF = 278 Hz, indole-C4), 137.8 (ArC), 135.7 (ArC), 132.
(d, overlapped, ArC), 132.1 (ArC), 129.2 (ArC), 126.8 (d, JCF = 10 H
ArC), 124.0 (ArC), 116.9 (d, JCF = 22 Hz, ArC), 109.9 (ArC), 106.
(ArC), 105.0 (d, JCF = 18 Hz, ArC), 42.0 (CH2).
5.1.3.4. 1-(4-Methoxy-1H-indol-2-yl)-2-pyridin-3-yl-ethanon
(7d). Prepared from commercial 4-methoxy-1H-indole-2-carbox
ylic acid methyl ester 3d (268 mg, 1.29 mmol) and 3-picolin
White solid (238 mg, 69%), mp 159–160 C (dec). LC–MS R
5.3 min (method 1); m/z [MH+] 267. 1H NMR d 11.75 (1H, br s, in
dole-H1), 8.52 (1H, br s, ArH), 8.42 (1H, d, J = 4.9 Hz, ArH), 7.70 (1H
d, J = 7.8 Hz, ArH), 7.57 (1H, br s, ArH), 7.32 (1H, dd, J = 7.6, 4.9 H
ArH), 7.17 (1H, t, J = 8.1 Hz, ArH), 6.97 (1H, d, J = 8.1 Hz, ArH), 6.5
(1H, d, J = 7.6 Hz, ArH), 4.33 (2H, s, CH2), 3.88 (3H, s, OCH3). 13
NMR d 189.7 (C@O), 154.9 (ArC), 151.1 (ArC), 148.3 (ArC), 139.
(ArC), 137.7 (ArC), 134.3 (ArC), 131.8 (ArC), 127.5 (ArC), 123.
(ArC), 118.8 (ArC), 108.3 (ArC), 106.1 (ArC), 100.0 (ArC), 55.
(OCH3), 41.8 (CH2). Anal. Calcd for C16H14N2O2: C, 72.16; H, 5.30
N, 10.52. Found: C, 72.36; H, 5.30; N, 10.36.
5.1.3.5. 1-(4-Hydroxy-1H-indol-2-yl)-2-pyridin-3-yl-ethanon
(7e). A solution of methoxyindole 7d (143 mg, 0.54 mmol) i
dry dichloromethane (5 mL) was cooled to 0 C and anhydrous alu
minum chloride (247 mg, 1.84 mmol) was added to give a yellow
suspension. Room temperature was slowly attained while the colo
of the reaction mixture gradually changed to dark red. After 19 h
as TLC still indicated presence of the starting compound, anothe
aliquot of aluminum chloride and 2 mL of dichloromethane wer
added. At 24 h of total reaction time (the majority of the startin
compound still being unconverted), the mixture was partitione
between ethyl acetate and water. The aqueous phase was extracte
with ethyl acetate and the combined organic layers were washe
with brine and dried over magnesium sulfate. Chromatograph
puriﬁcation (the title product eluted with 95–100% ethyl acetate
yielded alcohol ed 140-3 as an off-white solid (11 mg, 8%). LC
MS Rt 4.3 min (method 1); m/z [MH+] 253. 1H NMR d 11.59 (1H
br s, indole-H1), 9.88 (1H, br s, OH), 8.52 (1H, d, J = 1.8 Hz, ArH
8.42 (1H, dd, J = 4.6, 1.4 Hz, ArH), 7.70 (1H, d, J = 7.6 Hz, ArH
7.57 (1H, d, J = 1.6 Hz, ArH), 7.32 (1H, dd, J = 7.3, 4.6 Hz, ArH
7.03 (1H, t, J = 8.0 Hz, ArH), 6.82 (1H, d, J = 8.3 Hz, ArH), 6.37 (1H
d, J = 7.6 Hz, ArH), 4.32 (2H, s, CH2). 13C NMR d 189.5 (C@O
153.1 (ArC), 151.1 (ArC), 148.3 (ArC), 140.5 (ArC), 137.7 (ArC
134.0 (ArC), 131.8 (ArC), 127.6 (ArC), 123.9 (ArC), 118.7 (ArC
108.7 (ArC), 104.1 (ArC), 103.9 (ArC), 41.9 (CH2).
5.1.3.6. 1-(5-Fluoro-1H-indol-2-yl)-2-pyridin-3-yl-ethanone (7f
.Prepared from commercial 5-ﬂuoro-1H-indole-2-carboxylic aci
(186 mg, 1.02 mmol) and 3-picoline via corresponding acyl chlo
ride 3f (method A). Yellowish solid (62 mg, 24%), mp 194–197 C
LC–MS Rt 5.3 min (method 1); m/z [MH+] 255. 1H NMR d 11.8
(1H, br s, indole-H1), 8.51 (1H, br s, ArH), 8.43 (1H, d, J = 4.8 H
ArH), 7.70 (1H, d, J = 7.8 Hz, ArH), 7.53 (1H, br s, ArH), 7.46 (1H
dd, 3JHF = 9.6 Hz, 4JHH = 2.1 Hz, ArH), 7.42 (1H, dd, 3JHH = 9.1 H
4JHF = 4.7 Hz, ArH), 7.33 (1H, dd, J = 7.8, 4.8 Hz, ArH), 7.14 (1H, d
J = 9.2, 2.3 Hz, ArH), 4.36 (2H, s, CH2). 13C NMR d 190.2 (C@O
157.8 (d, JCF = 233 Hz, indole-C5), 151.1 (ArC), 148.4 (ArC), 137.
(ArC), 136.8 (ArC), 135.2 (ArC), 131.4 (ArC), 127.4 (d, JCF = 10 H
ArC), 124.0 (ArC), 115.2 (d, JCF = 27 Hz, ArC), 114.7 (d, JCF = 10 H
ArC), 110.3 (d, JCF = 5 Hz, indole-C7a), 107.1 (d, JCF = 23 Hz, ArC
42.1 (CH2). 19F NMR d 122.4. Anal. Calcd for C15H11FN2O: C
70.86; H, 4.36; N, 11.02. Found: C, 70.61; H, 4.36; N, 10.87.Please cite this article in press as: Dolušic´, E.; et al. Bioorg. Med. Che5.1.3.7. 1-(5-Chloro-1H-indol-2-yl)-2-pyridin-3-yl-ethanon
(7g). Prepared from commercial 5-chloro-1H-indole-2-carboxyl
acid (355 mg, 1.78 mmol) and 3-picoline via corresponding acy
chloride 3g (method A). Yellow solid (137 mg, 29%), mp 206
208 C (dec). LC–MS Rt 5.8 min (method 1); m/z [MH+] 271. 1
NMR d 11.97 (1H, br s, indole-H1), 8.51 (1H, br s, ArH), 8.43 (1H
d, J = 4.8 Hz, ArH), 7.77 (1H, br s, ArH), 7.70 (1H, d, J = 7.8 H
ArH), 7.52 (1H, br s, ArH), 7.43 (1H, d, J = 8.7 Hz, ArH), 7.33 (1H
dd, J = 7.8, 4.8 Hz, ArH), 7.26 (1H, dd, J = 8.7, 1.8 Hz, ArH), 4.3
(2H, s, CH2). 13C NMR d 190.3 (C@O), 151.1 (ArC), 148.4 (ArC
137.9 (ArC), 136.8 (ArC), 136.6 (ArC), 131.3 (ArC), 128.4 (ArC
126.3 (ArC), 125.3 (ArC), 124.0 (ArC), 122.2 (ArC), 115.0 (ArC
109.8 (ArC), 42.1 (CH2). Anal. Calcd for C15H11ClN2O: C, 66.55; H
4.10; N, 10.35. Found: C, 67.48; H, 4.11; N, 9.99.
5.1.3.8. 1-(5-Bromo-1H-indol-2-yl)-2-pyridin-3-yl-ethanone (7h
.Prepared from commercial 5-bromo-1H-indole-2-carboxylic aci
(260 mg, 1.08 mmol) and 3-picoline via corresponding acyl chlo
ride 3h (method A). White solid (79 mg, 23%), decomposes withou
melting at 224–226 C. LC–MS Rt 6.0 min (method 1), 13.3 mi
(method 2); m/z [MH+] 315; 317. 1H NMR d 11.99 (1H, br s, in
dole-H1), 8.51 (1H, d, J = 1.8 Hz, ArH), 8.43 (1H, dd, J = 4.8, 1.2 H
ArH), 7.92 (1H, br s, ArH), 7.70 (1H, d, J = 7.8 Hz, ArH), 7.52 (1H
d, J = 1.6 Hz, ArH), 7.37 (2H, overlapped, 2 ArH), 7.33 (1H, dd
J = 7.8, 4.8 Hz, ArH), 4.38 (2H, s, CH2). 13C NMR d 190.3 (C@O
151.2 (ArC), 148.4 (ArC), 137.9 (ArC), 137.0 (ArC), 136.4 (ArC
131.3 (ArC), 129.1 (ArC), 128.7 (ArC), 125.3 (ArC), 124.0 (ArC
115.4 (ArC), 113.2 (ArC), 109.6 (ArC), 42.1 (CH2). Anal. Calcd fo
C15H11BrN2O: C, 57.16; H, 3.52; N, 8.89. Found: C, 57.00; H, 3.31
N, 8.40.
5.1.3.9. 1-(5-Methyl-1H-indol-2-yl)-2-pyridin-3-yl-ethanone (7i
Prepared from commercial 5-methyl-1H-indole-2-carboxylic aci
(482 mg, 2.75 mmol) and 3-picoline via corresponding acyl chlo
ride 3i (method A). Yellowish solid (114 mg, 17%), mp 181
182 C (dec). LC–MS Rt 5.7 min (method 1); m/z [MH+] 251. 1
NMR d 11.64 (1H, br s, indole-H1), 8.52 (1H, br s, ArH), 8.42 (1H
d, J = 3.9 Hz, ArH), 7.70 (1H, d, J = 7.8 Hz, ArH), 7.46 (2H, br
2ArH), 7.34–7.29 (2H, m, 2ArH), 7.09 (1H, d, J = 8.5 Hz, ArH), 4.3
(2H, s, CH2), 2.34 (3H, s, CH3). 13C NMR d 190.0 (C@O), 151.
(ArC), 148.3 (ArC), 137.7 (ArC), 137.1 (ArC), 135.4 (ArC), 131.
(ArC), 129.6 (ArC), 128.2 (ArC), 127.7 (ArC), 123.9 (ArC), 122.
(ArC), 113.0 (ArC), 110.1 (ArC), 42.0 (CH2), 21.6 (CH3). Anal. Calc
for C16H14N2O: C, 76.78; H, 5.64; N, 11.19. Found: C, 77.04; H
5.52; N, 10.90.
5.1.3.10. 1-(5-Methoxy-1H-indol-2-yl)-2-pyridin-3-yl-ethanone
(7j) and 1-(7-methoxy-1H-indol-2-yl)-2-pyridin-3-yl-ethanon
(7q)43. Prepared from a 1:1 mixture (method B; 208 m
0.95 mmol) of 5-methoxy-1H-indole-2-carboxylic acid ethyl este
(3j) and 7-methoxy-1H-indole-2-carboxylic acid ethyl ester (3q
and 3-picoline. The two ﬁnal products were separated by chroma
tography. 7j: (Sundberg 1978) eluted with 80% ethyl acetate. Ye
lowish solid (88 mg, 35%). LC–MS Rt 5.1 min (method 1), 8.4 mi
(method 2); m/z [MH+] 267. 1H NMR d 11.64 (1H, br s, indole
H1), 8.52 (1H, d, J = 2.0 Hz, ArH), 8.43 (1H, dd, J = 4.7, 1.5 H
ArH), 7.70 (1H, dt, J = 7.8, 1.8 Hz, ArH), 7.44 (1H, d, J = 1.8 H
ArH), 7.34–7.29 (2H, overlapped, 2 ArH), 7.11 (1H, d, J = 2.4 H
ArH), 6.92 (1H, dd, J = 8.9, 2.4 Hz, ArH), 4.33 (2H, s, CH2), 3.7
(3H, s, OCH3). 13C NMR d 189.8 (C@O), 154.6 (ArC), 147.4 (ArC
135.6 (ArC), 134.0 (ArC), 132.2 (ArC), 132.1 (2 ArC), 129.2 (ArC
127.7 (ArC), 118.0 (ArC), 114.3 (ArC), 110.1 (ArC), 102.8 (ArC
55.8 (OCH3), 42.0 (CH2). 7q: eluted with 70% ethyl acetate. Whit
solid (111 mg, 44%), mp 171–175 C (dec). LC–MS Rt 5.3 mim. (2010), doi:10.1016/j.bmc.2010.12.032
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Plethod 1), 8.7 min (method 2); m/z [MH+] 267. 1H NMR d 11.72
H, br s, indole-H1), 8.51 (1H, d, J = 1.6 Hz, ArH), 8.42 (1H, d,
3.4 Hz, ArH), 7.69 (1H, d, J = 8.0 Hz, ArH), 7.50 (1H, d,
1.4 Hz, ArH), 7.32 (1H, dd, J = 7.7, 4.7 Hz, ArH), 7.25 (1H, d,
8.0 Hz, ArH), 6.99 (1H, t, J = 7.9 Hz, ArH), 6.79 (1H, d,
7.6 Hz, ArH), 4.35 (2H, s, CH2), 3.87 (3H, s, OCH3). 13C NMR d
9.7 (C@O), 151.1 (ArC), 148.3 (ArC), 147.4 (ArC), 137.8 (ArC),
5.6 (ArC), 131.6 (ArC), 129.5 (ArC), 128.8 (ArC), 123.9 (ArC),
1.6 (ArC), 115.3 (ArC), 111.0 (ArC), 105.6 (ArC), 55.9 (OCH3),
.2 (CH2). Anal. Calcd for C16H14N2O2: C, 72.16; H, 5.30; N,
.52. Found: C, 72.90; H, 5.14; N, 10.20.
.3.11. 1-(5-Nitro-1H-indol-2-yl)-2-pyridin-3-yl-ethanone (7k).
epared from commercial 5-nitro-1H-indole-2-carboxylic acid
hyl ester 3k (249 mg, 1.01 mmol) and 3-picoline. Reaction time:
h. Bright yellow solid (42 mg, 15%). LC–MS Rt 5.3 min (method
; m/z [MH+] 282. 1H NMR d 12.46 (1H, br s, indole-H1), 8.75
H, br s, ArH), 8.52 (1H, br s, ArH), 8.44 (1H, d, J = 4.6 Hz, ArH),
2 (1H, d, J = 9.2 Hz, ArH), 7.82 (1H, s, ArH), 7.71 (1H, d,
7.8 Hz, ArH), 7.57 (1H, d, J = 9.2 Hz, ArH), 7.34 (1H, dd, J = 8.0,
Hz, ArH), 4.44 (2H, s, CH2).
.3.12. 1-(5-Phenyl-1H-indol-2-yl)-2-pyridin-3-ylethanone (7l)46.
epared according to a literature procedure. A suspension of tetra-
(triphenylphosphine)palladium (0) (7 mg, 6 lmol) in a mixture
1 M potassium carbonate (0.8 mL), ethanol (0.8 mL) and toluene
.8 mL) was added to a stirred suspension of bromoindole 7h
8 mg, 0.12 mmol) and phenylboronic acid (33 mg, 0.26 mmol)
a 1:1 mixture of toluene and ethanol (0.8 mL). The (initially
hre colored) suspension was heated at reﬂux temperature for
h, allowed to cool down to room temperature and diluted with
hyl acetate. Evaporation with silica and chromatographic puriﬁ-
tion afforded the title product as a bright yellow solid (12 mg,
%). LC–MS Rt 6.5 min (method 1), 10.2 min (method 2); m/z
H+] 313. 1H NMR d 11.85 (1H, br s, indole-H1), 8.54 (1H, d,
1.8 Hz, ArH), 8.44 (1H, dd, J = 4.8, 1.6 Hz, ArH), 7.96 (1H, br s,
H), 7.72 (1H, dt, J = 7.8, 1.8 Hz, ArH), 7.67–7.49 (5H, overlapped,
ArH), 7.43 (2H, t, J = 7.7 Hz, 2 ArH), 7.33 (1H, dd, J = 8.0, 2.7 Hz,
H), 7.29 (1H, t, J = 7.2 Hz, ArH), 4.39 (2H, s, CH2). 13C NMR d
0.1 (C@O), 151.1 (ArC), 148.3 (ArC), 141.6 (ArC), 138.1 (ArC),
7.8 (ArC), 136.1 (ArC), 134.6 (ArC), 132.1 (ArC), 132.0 (ArC),
9.42 (2 ArC), 129.36 (ArC), 127.3 (2 ArC), 125.9 (ArC), 124.0
rC), 121.0 (ArC), 113.8 (ArC), 111.0 (ArC), 42.1 (CH2). Anal. Calcd
r C21H16N2O: C, 80.75; H, 5.16; N, 8.97. Found: C, 80.01; H, 5.23;
8.49.
.3.13. 2-Pyridin-3-yl-1-(5-triﬂuoromethoxy-1H-indol-2-yl)-
hanone (7m). Prepared from commercial 5-triﬂuoromethoxy-
-indole-2-carboxylic acid (256 mg, 1.01 mmol) and 3-picoline
corresponding acyl chloride 3m (method A). Yellowish solid
0 mg, 28%), mp 184–186 C. LC–MS Rt 6.2 min (method 1); m/z
H+] 321. 1H NMR d 12.04 (1H, br s, indole-H1), 8.52 (1H, d,
1.6 Hz, ArH), 8.43 (1H, dd, J = 4.6, 1.4 Hz, ArH), 7.71–7.69 (2H,
erlapped, 2ArH), 7.60 (1H, br s, ArH), 7.50 (1H, d, J = 8.9 Hz,
H), 7.33 (1H, dd, J = 7.8, 4.8 Hz, ArH), 7.24 (1H, d, J = 8.9 Hz,
H), 4.38 (2H, s, CH2). 13C NMR d 190.3 (C@O), 151.1 (ArC),
8.4 (ArC), 142.9 (ArC), 137.8 (ArC), 137.1 (ArC), 136.8 (ArC),
1.3 (ArC), 127.3 (ArC), 124.0 (ArC), 120.9 (d, JCF = 254 Hz,
F3), 120.1 (ArC), 115.2 (ArC), 114.8 (ArC), 110.6 (ArC), 42.1
H2). 19F NMR d 56.9. Anal. Calcd for C16H11F3N2O2: C, 60.00;
3.46; N, 8.75. Found: C, 59.95; H, 3.43; N, 8.45.
.3.14. 1-(5-Benzyloxy-1H-indol-2-yl)-2-pyridin-3-yl-ethanone
n). Prepared from commercial 5-benzyloxy-1H-indole-2-car-
xylic acid ethyl ester 3n (499 mg, 1.69 mmol) and 3-picoline.
f-white solid (166 mg, 29%), mp 183–184 C. LC–MS Rt 6.5 minease cite this article in press as: Dolušic´, E.; et al. Bioorg. Med. Chem. (2ethod 1), 14.8 min (method 2); m/z [MH+] 343. 1H NMR d
.65 (1H, br s, indole-H1), 8.52 (1H, br s, ArH), 8.42 (1H, d,
4.8 Hz, ArH), 7.70 (1H, d, J = 7.8 Hz, ArH), 7.45–7.43 (3H, over-
ped, 3ArH), 7.38–7.27 (5H, overlapped, 5ArH), 7.21 (1H, d,
1.8 Hz, ArH), 7.00 (1H, dd, J = 8.9, 2.3 Hz, ArH), 5.08 (2H, s, ben-
l CH2), 4.32 (2H, s, C(O)CH2). 13C NMR d 189.9 (C@O), 153.5 (ArC),
1.1 (ArC), 148.3 (ArC), 137.9 (ArC), 137.7 (ArC), 135.8 (ArC),
4.1 (ArC), 131.7 (ArC), 128.9 (2C, 2 phenyl C), 128.3 (ArC),
8.2 (2C, 2 phenyl C), 127.7 (ArC), 124.0 (ArC), 118.5 (ArC),
4.3 (ArC), 110.2 (ArC), 104.4 (ArC), 70.1 (benzyl CH2), 42.0
(O)CH2). Anal. Calcd for C22H18N2O2: C, 77.17; H, 5.30; N, 8.18.
und: C, 76.95; H, 5.01; N, 8.10.
.3.15. 1-(5-Hydroxy-1H-indol-2-yl)-2-pyridin-3-yl-ethanone
o) and 2-(1-hydroxy-2-pyridin-3-ylethyl)-1H-indol-5-ol
7). Ammonium formate (485 mg, 7.50 mmol) and Pd black (sur-
e area 40–60 m2/g, 110 mg, 1.03 mmol) were added to a stirred
spension of benzyl ether 7n (166 mg, 0.13 mmol) in dry metha-
l (55 mL). The blue-greenish suspension was stirred at room
mperature for 1 h and ﬁltered through Celite 545. The ﬁlter
s extensively washed with methanol and the combined ﬁltrate
d washings were concentrated under reduced pressure. Chro-
atographic puriﬁcation yielded hydroxyindole 7o (eluted with
% ethyl acetate; 38 mg, 31%) and byproduct 17 (eluted with
0% ethyl acetate; 69 mg, 56%). Shortening the reaction time to
min afforded 7o as the only product in a 58% yield. Analytical
ta: 7o, yellow solid which decomposes without melting above
0 C. LC–MS Rt 4.1 min (method 1); m/z [MH+] 253. 1H NMR d
.49 (1H, br s, indole-H1), 8.97 (1H, s, OH), 8.51 (1H, br s, ArH),
2 (1H, d, J = 3.6 Hz, ArH), 7.69 (1H, dt, 3JHH = 7.8 Hz,
H = 1.8 Hz, ArH), 7.36 (1H, d, J = 1.8 Hz, ArH), 7.32 (1H, dd,
7.8, 4.8 Hz, ArH), 7.22 (1H, d, J = 8.9 Hz, ArH), 6.93 (1H, d,
2.3 Hz, ArH), 6.81 (1H, dd, J = 8.7, 2.3 Hz, ArH), 4.29 (2H, s,
2). 13C NMR d 189.8 (C@O), 152.0 (ArC), 151.1 (ArC), 148.3
rC), 137.7 (ArC), 135.6 (ArC), 133.5 (ArC), 131.7 (ArC), 128.1
rC), 123.9 (ArC), 118.0 (ArC), 113.9 (ArC), 109.6 (ArC), 105.3
rC), 41.9 (CH2). Compound 17, yellowish solid, mp 188–190 C.
–MS Rt 3.1 min (method 1); m/z [MH+] 255. 1H NMR d 10.68
H, br s, indole-H1), 8.50 (1H, br s, ArH), 8.33–8.32 (2H, over-
ped, ArH, OH on indole), 7.55 (1H, dd, 3JHH = 7.8 Hz,
H = 1.8 Hz, ArH), 7.22 (1H, dd, J = 7.8, 4.8 Hz, ArH), 7.08 (1H, d,
8.6 Hz, ArH), 6.70 (1H, d, J = 2.0 Hz, ArH), 6.50 (1H, dd,
H = 8.6 Hz, 4JHH = 2.3 Hz, ArH), 6.01 (1H, d, J = 1.4 Hz, ArH), 5.44
H, d, J = 5.3 Hz, CHOH), 4.81 (1H, m, CHOH), 3.07 (1H, dd,
H = 13.6 Hz, 3JHH = 5.4 Hz, CH2), 2.97 (1H, dd, 2JHH = 13.6 Hz,
H = 8.0 Hz, CH2). 13C NMR d 151.0 (ArC), 150.9 (ArC), 147.7
rC), 143.4 (ArC), 137.3 (ArC), 134.9 (ArC), 131.0 (ArC), 128.9
rC), 123.6 (ArC), 111.9 (ArC), 111.2 (ArC), 104.2 (ArC), 97.7
rC), 68.4 (CHOH), 41.0 (CH2).
.3.16. 1-(6-Fluoro-1H-indol-2-yl)-2-pyridin-3-yl-ethanone
p). Prepared from 6-ﬂuoro-1H-indole-2-carboxylic acid ethyl
ter 3p (method B; 80 mg, 0.39 mmol) and 3-picoline. Bright yel-
solid (59 mg, 60%), mp 192–193 C (dec). LC–MS Rt 5.4 min
ethod 1); m/z [MH+] 255. 1H NMR d 11.86 (1H, br s, indole-
), 8.52 (1H, d, J = 1.7 Hz, ArH), 8.43 (1H, dd, J = 4.9, 1.7 Hz,
H), 7.74 (1H, dd, overlapped, ArH), 7.71 (1H, d, overlapped,
H), 7.60 (1H, d, J = 1.4 Hz, ArH), 7.33 (1H, dd, J = 7.7, 4.9 Hz,
H), 7.11 (1H, dd, 3JHF = 9.9 Hz, 4JHH = 1.9 Hz, ArH), 6.95 (1H, dt,
= 9.3 Hz, 4J = 1.9 Hz, ArH), 4.34 (2H, s, CH2). 13C NMR d 189.8
@O), 161.6 (d, JCF = 219 Hz, indole-C6), 151.1 (ArC), 148.4 (ArC),
8.6 (d, JCF = 13 Hz, ArC), 137.8 (ArC), 136.3 (d, JCF = 3 Hz, indole-
a), 131.5 (ArC), 125.1 (d, JCF = 11 Hz, ArC), 124.4 (ArC), 124.0
rC), 110.9 (ArC), 110.4 (d, JCF = 26 Hz, ArC), 98.6 (d, JCF = 26 Hz,
C), 41.9 (CH2). 19F NMR d 115.0. Anal. Calcd for C15H11FN2O:
70.86; H, 4.36; N, 11.02. Found: C, 71.12; H, 4.72; N, 10.81.010), doi:10.1016/j.bmc.2010.12.032
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22 December 20105.1.3.17. 1-(4-Benzyloxy-5-methoxy-1H-indol-2-yl)-2-pyridin-3
yl-ethanone (7r). Prepared from 4-benzyloxy-5-methoxy-1H-in
dole-2-carboxylic acid ethyl ester 3r (method B; 282 m
0.87 mmol) and 3-picoline. Yellow solid (84 mg, 26%), mp 137
139 C. LC–MS Rt 6.3 min (method 1), 15.7 min (method 2); m
[MH+] 373. 1H NMR d 11.65 (1H, br s, indole-H1), 8.51 (1H, br
ArH), 8.43 (1H, d, J = 4.1 Hz, ArH), 7.69 (1H, d, J = 7.8 Hz, ArH
7.54–7.50 (3H, overlapped, 3ArH), 7.38–7.30 (4H, overlapped
4ArH), 7.14 (1H, d, J = 8.8 Hz, ArH), 7.07 (1H, d, J = 8.8 Hz, ArH
5.22 (2H, s, benzyl CH2), 4.36 (2H, s, C(O)CH2), 3.79 (3H s, OCH3
13C NMR d 190.0 (C@O), 151.1 (ArC), 148.3 (ArC), 144.8 (ArC
141.5 (ArC), 138.4 (ArC), 137.8 (ArC), 135.6 (ArC), 131.6 (ArC
128.8 (2 ArC), 128.6 (2 ArC), 128.4 (ArC), 124.0 (ArC), 122.
(ArC), 117.4 (ArC), 108.4 (ArC), 107.8 (ArC), 74.6 (benzyl CH2
58.5 (OCH3), 41.9 (C(O)CH2). Anal. Calcd for C23H20N2O3: C
74.18; H, 5.41; N, 7.52. Found: C, 74.98; H, 5.29; N, 7.42.
5.1.3.18. 1-(4-Hydroxy-5-methoxy-1H-indol-2-yl)-2-pyridin-3
yl-ethanone (7s). Benzyl ester 7r (59 mg, 0.16 mmol) was dis
solved in absolute ethanol (15 mL) to give a clear yellow solutio
to which 3% Pd on activated carbon (60 mg, 17 lmol) was added
The ﬂask was evacuated and back-ﬁlled with hydrogen gas (re
peated three times). The suspension was stirred at room tempera
ture for 45 min (until TLC indicated reaction completion) an
ﬁltered through Celite 545. The ﬁlter was extensively washed wit
ethyl acetate and the combined ﬁltrate and washings were concen
trated under reduced pressure. Chromatographic puriﬁcation (th
title product eluted with 80–90% ethyl acetate) afforded the titl
hydroxyindole 7s as a light brown half-solid in a 53% (24 mg) yield
LC–MS Rt 4.3 min (method 1);m/z [MH+] 283. 1H NMR d 11.47 (1H
br s, indole-H1), 9.26 (1H, s, OH), 8.52 (1H, br s, ArH), 8.42 (1H, d
J = 3.9 Hz, ArH), 7.70 (1H, d, J = 7.6 Hz, ArH), 7.54 (1H, d, J = 1.4 H
ArH), 7.33 (1H, dd, J = 7.8, 4.8 Hz, ArH), 7.04 (1H, d, J = 8.7 Hz, ArH
6.78 (1H, d, J = 8.7 Hz, ArH), 4.31 (2H, s, CH2), 3.72 (3H s, OCH3). 13
NMR d 189.6 (C@O), 151.1 (ArC), 148.3 (ArC), 141.2 (ArC), 139.
(ArC), 137.7 (ArC), 136.0 (ArC), 134.9 (ArC), 131.8 (ArC), 124.
(ArC), 119.8 (ArC), 117.8 (ArC), 108.4 (ArC), 103.4 (ArC), 59.
(OCH3), 41.9 (CH2).
5.1.3.19. 1-(4,6-Dichloro-1H-indol-2-yl)-2-pyridin-3-yl-ethanon
(7t). Prepared from commercial 4,6-dichloro-1H-indole-2-carbony
chloride 3t (647 mg, 2.47 mmol) and 3-picoline. Off-white soli
(198 mg, 26%), mp 223–225 C. LC–MS Rt 6.5 min (method 1); m
[MH+] 305. 1H NMR d 12.26 (1H, br s, indole-H1), 8.52 (1H, d
J = 1.7 Hz, ArH), 8.44 (1H, dd, J = 4.8, 1.7 Hz, ArH), 7.70 (1H, d
J = 7.8, 1.7 Hz, ArH), 7.62 (1H, br s, ArH), 7.41 (1H, dd, J = 1.6, 0.9 H
ArH), 7.33 (1H, dd, J = 7.8, 4.8 Hz, ArH), 7.27 (1H, d, J = 1.8 Hz, ArH
4.44 (2H, s, CH2). 13C NMR d 190.3 (C@O), 151.2 (ArC), 148.4 (ArC
138.7 (ArC), 137.9 (ArC), 136.8 (ArC), 131.2 (ArC), 130.4 (ArC
128.2 (ArC), 125.2 (ArC), 124.0 (ArC), 120.7 (ArC), 112.0 (ArC), 108.
(ArC), 42.0 (CH2). Anal. Calcd for C15H10Cl2N2O: C, 59.04; H, 3.30; N
9.18. Found: C, 59.79; H, 3.26; N, 9.21.
5.1.3.20. 1-(4,6-Dimethoxy-1H-indol-2-yl)-2-pyridin-3-yl-etha
none (7u). Prepared from commercial 4,6-dimethoxy-1H-indole
2-carboxylic acid methyl ester 3u (241 mg, 1.01 mmol) and 3-pic
oline. Off-white solid (240 mg, 80%), mp 195–197 C. LC–MS R
5.3 min (method 1); m/z [MH+] 297. 1H NMR d 11.60 (1H, s, in
dole-H1), 8.52 (1H, d, J = 1.6 Hz, ArH), 8.41 (1H, dd, J = 4.8, 1.6 H
ArH), 7.69 (1H, dt, J = 7.8, 0.9 Hz, ArH), 7.51 (1H, d, J = 1.8 H
ArH), 7.31 (1H, dd, J = 7.8, 4.8 Hz, ArH), 6.40 (1H, d, J = 1.5 H
ArH), 6.17 (1H, d, J = 1.5 Hz, ArH), 4.25 (2H, s, CH2), 3.84 (3H,
OCH3), 3.73 (3H, s, OCH3). 13C NMR d 188.6 (C@O), 160.8 (ArC
155.4 (ArC), 151.0 (ArC), 148.2 (ArC), 140.6 (ArC), 137.6 (ArC
133.5 (ArC), 132.0 (ArC), 123.9 (ArC), 113.8 (ArC), 109.2 (ArC
93.1 (ArC), 87.0 (ArC), 55.83 (OCH3), 55.76 (OCH3), 41.5 (CH2). AnaPlease cite this article in press as: Dolušic´, E.; et al. Bioorg. Med. CheCalcd for C17H16N2O3: C, 68.91; H, 5.44; N, 9.45. Found: C, 69.65; H
5.17; N, 9.40.
5.1.3.21. 1-(1H-Indol-2-yl)-2-pyridin-3-yl-propan-1-one (7v
Prepared from commercial 1H-indole-2-carboxylic acid ethyl este
3a (983 mg, 5.04 mmol) and 3-ethylpyridine. Yellow half-soli
(220 mg, 17%). LC–MS Rt 5.7 min (method 1), 7.3 min (metho
2); m/z [MH+] 251. 1H NMR d 11.74 (1H, br s, indole-H1), 8.6
(1H, d, J = 1.7 Hz, ArH), 8.39 (1H, dd, J = 4.8, 1.7 Hz, ArH), 7.7
(1H, dt, J = 7.8, 1.7 Hz, ArH), 7.64 (1H, d, J = 8.2 Hz, ArH), 7.5
(1H, d, J = 1.4 Hz, ArH), 7.37 (1H, d, J = 8.5 Hz, ArH), 7.31 (1H, dd
J = 7.9, 4.7 Hz, ArH), 7.23 (1H, t, J = 7.7 Hz, ArH), 7.03 (1H,
J = 7.4 Hz, ArH), 4.89 (1H, q, J = 7.0 Hz, CHCH3), 1.46 (3H, d
J = 7.0 Hz, CH3). 13C NMR d 193.0 (C@O), 149.7 (ArC), 148.6 (ArC
138.6 (ArC), 137.7 (ArC), 135.5 (ArC), 134.7 (ArC), 127.3 (ArC
126.3 (ArC), 124.3 (ArC), 123.3 (ArC), 120.9 (ArC), 113.3 (ArC
110.7 (ArC), 44.5 (CHCH3), 19.1 (CH3).
5.1.3.22. 1-(1H-Indol-2-yl)-2-pyridin-2-yl-ethanone (8a). Pre
pared from commercial 1H-indole-2-carboxylic acid ethyl este
3a (218 mg, 1.12 mmol) and 2-picoline. Yellow solid (237 m
90%), mp 140–141 C. LC–MS Rt 5.5 min (method 1), 9.7 mi
(method 2); m/z [MH+] 237. 1H NMR d 11.75 (1H, br s, indole
H1), 8.45 (1H, dd, J = 4.8, 0.9 Hz, ArH), 7.72 (1H, dd, J = 7.6
1.8 Hz, ArH), 7.67 (1H, d, J = 8.0 Hz, ArH), 7.44 (1H, d, J = 1.6 H
ArH), 7.42–7.38 (2H, overlapped, 2 ArH), 7.26–7.21 (2H, over
lapped, 2 ArH), 7.04 (1H, t, J = 7.7 Hz, ArH), 4.43 (2H, s, CH2). 13
NMR d 190.0 (C@O), 156.4 (ArC), 149.7 (ArC), 138.4 (ArC), 137.
(ArC), 135.8 (ArC), 127.4 (ArC), 126.1 (ArC), 124.9 (ArC), 123.
(ArC), 122.4 (ArC), 120.8 (ArC), 113.3 (ArC), 110.8 (ArC), 48.
(CH2). Anal. Calcd for C15H12N2O: C, 76.25; H, 5.12; N, 11.86
Found: C, 76.09; H, 5.06; N, 11.74.
5.1.3.23. 1-(1H-Indol-2-yl)-2-pyridin-4-yl-ethanone (9a)47. Pre
pared from commercial 1H-indole-2-carboxylic acid ethyl este
3a (220 mg, 1.13 mmol) and 4-picoline. Bright yellow soli
(240 mg, 90%), mp 169–170 C. LC–MS Rt 5.0 min (method 1
8.1 min (method 2); m/z [MH+] 237. 1H NMR d 11.79 (1H, br s, in
dole-H1), 8.48 (2H, d, J = 6.0 Hz, 2 ArH), 7.68 (1H, d, J = 8.0 Hz, ArH
7.55 (1H, d, J = 1.1 Hz, ArH), 7.41 (1H, dd, J = 8.3, 0.8 Hz, ArH), 7.3
(2H, d, J = 6.0 Hz, 2 ArH), 7.26 (1H, dt, J = 7.7, 1.1 Hz, ArH), 7.06 (1H
dt, J = 7.5, 0.8 Hz, ArH), 4.35 (2H, s, CH2). 13C NMR d 189.5 (C@O
150.0 (2 ArC), 144.8 (ArC), 138.6 (ArC), 135.4 (ArC), 127.4 (ArC
126.3 (2 ArC), 125.6 (ArC), 123.3 (ArC), 120.9 (ArC), 113.3 (ArC
110.9 (ArC), 44.2 (CH2). Anal. Calcd for C15H12N2O: C, 76.25; H
5.12; N, 11.86. Found: C, 75.68; H, 5.09; N, 11.73.
5.1.3.24. 1-(1H-Indol-2-yl)-2-pyrazin-2-yl-ethanone (10a). Pre
pared from commercial 1H-indole-2-carboxylic acid ethyl este
3a (195 mg, 1.00 mmol) and 2-methylpyrazine. Yellow soli
(97 mg, 41%), mp 175–176 C. LC–MS Rt 5.5 min (method 1
11.0 min (method 2); m/z [MH+] 238. 1H NMR d 11.80 (1H, br s, in
dole-H1), 8.69 (1H, d, J = 1.6 Hz, ArH), 8.56 (1H, dd, J = 2.5, 1.6 H
ArH), 8.51 (1H, d, J = 2.5 Hz, ArH), 7.69 (1H, d, J = 8.0 Hz, ArH
7.51 (1H, d, J = 1.6 Hz, ArH), 7.41 (1H, d, J = 8.3 Hz, ArH), 7.2
(1H, dt, J = 7.7, 0.9 Hz, ArH), 7.06 (1H, dt, J = 7.6, 0.7 Hz, ArH
4.57 (2H, s, CH2). 13C NMR d 189.3 (C = O), 152.4 (ArC), 146.
(ArC), 144.7 (ArC), 143.4 (ArC), 138.5 (ArC), 135.5 (ArC), 127.
(ArC), 126.3 (ArC), 123.3 (ArC), 120.9 (ArC), 113.3 (ArC), 110.
(ArC), 45.1 (CH2). Anal. Calcd for C14H11N3O: C, 70.87; H, 4.67; N
17.71. Found: C, 70.03; H, 4.63; N, 17.63.
5.1.3.25. 1-(1H-Indol-2-yl)-2-phenylethanone (11a)36,48 and 2
(1H-indol-2-yl)-1,3-diphenylpropan-2-ol (16). An oven-drie
ﬂask was purged with argon while hot, then allowed to cool dow
to room temperature under argon and charged with dry THF (1 mLm. (2010), doi:10.1016/j.bmc.2010.12.032
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Pld benzyl magnesium chloride, 2.0 M solution in THF (1 mL,
mmol) to give a clear grayish–yellowish solution. The solution
s cooled in an ice/water bath and a solution of 1H-indole-2-car-
xylic acid ethyl ester 3a (104 mg, 0.53 mmol) in dry THF (2 mL)
s added dropwise over the ﬂask wall. Clear yellowish solution
s allowed to attain room temperature overnight. After 22 h of
tal reaction time (the mixture turned greenish), the reaction
s quenched with saturated aqueous ammonium chloride solu-
n (5 mL). Upon stirring for several minutes, the mixture was par-
ioned between ethyl acetate and water. The aqueous phase was
tracted with ethyl acetate and the combined organic layers were
shed with brine and dried over MgSO4. Chromatographic puriﬁ-
tion yielded the two products: 11a: eluted with 7% ethyl ace-
te. Yellowish solid (46 mg, 37%), mp 125–133 C. LC–MS Rt
min (method 1), 16.6 min (method 2); m/z [MH+] 236. 1H
R d 11.73 (1H, br s, indole-H1), 7.67 (1H, d, J = 8.0 Hz, ArH),
3 (1H, m, ArH), 7.40 (1H, d, J = 8.2 Hz, ArH), 7.33–7.20 (6H, over-
ped, 6 ArH), 7.05 (1H, dt, J = 7.6, 0.9 Hz, ArH), 4.25 (2H, s, CH2).
NMR d 190.8 (C@O), 138.5 (ArC), 136.0 (ArC), 135.6 (ArC), 130.0
ArC), 128.9 (2 ArC), 127.4 (ArC), 127.1 (ArC), 126.1 (ArC), 123.2
rC), 120.8 (ArC), 113.3 (ArC), 110.7 (ArC), 45.1 (CH2). Anal. Calcd
r C16H13NO: C, 81.68; H, 5.57; N, 5.95. Found: C, 80.67; H, 6.16; N,
1. 16: eluted with 9% ethyl acetate. White solid (30 mg, 17%),
p 160–163 C. LC–MS Rt 7.2 min (method 1), 19.0 min (method
; m/z [MH+] 328. 1H NMR d 10.75 (1H, br s, indole-H1), 7.31
H, d, J = 7.8 Hz, ArH), 7.27 (1H, d, J = 8.0 Hz, ArH), 7.09–7.03
H, overlapped, 6 ArH), 6.98–6.96 (4H, overlapped, 4 ArH), 6.92
H, dt, J = 7.5, 1.0 Hz, ArH), 6.84 (1H, dt, J = 7.3, 0.9 Hz, ArH),
4 (1H, d, J = 1.4 Hz, ArH), 5.18 (1H, s, OH), 3.17 (2H, d,
m = 13.5 Hz, CH2), 3.04 (2H, d, Jgem = 13.5 Hz, CH2). 13C NMR d
4.7 (ArC), 138.1 (2C, ArC), 136.2 (ArC), 131.0 (4C, ArC), 128.3
rC), 127.9 (4C, ArC), 126.3 (2C, ArC), 120.5 (ArC), 119.9 (ArC),
8.9 (ArC), 111.6 (ArC), 98.9 (ArC), 75.0 (COH), 48.0 (2C, CH2).
al. Calcd for C23H21NO: C, 84.37; H, 6.46; N, 4.28. Found: C,
.84; H, 6.82; N, 3.91.
.3.26. 1-(1-Methyl-1H-indol-2-yl)-2-pyridin-3-yl-ethanone
2a)43. Prepared from 1-methyl-1H-indole-2-carboxylic acid
ethyl ester 6a (method C; 544 mg, 2.88 mmol) and 3-picoline.
ight yellow solid (243 mg, 34%), mp 75–77 C. LC–MS Rt
min (method 1); m/z [MH+] 251. 1H NMR d 8.51 (1H, s, ArH),
3 (1H, d, J = 4.6 Hz, ArH), 7.74–7.69 (3H, overlapped, 3 ArH),
5 (1H, d, J = 8.5 Hz, ArH), 7.37–7.31 (2H, overlapped, 2 ArH),
3 (1H, t, J = 7.5 Hz, ArH), 4.39 (2H, s, CH2), 3.95 (3H, s, CH3).
NMR d 191.2 (C@O), 151.1 (ArC), 148.3 (ArC), 140.4 (ArC),
7.8 (ArC), 134.5 (ArC), 131.7 (ArC), 126.5 (ArC), 125.9 (ArC),
3.9 (ArC), 123.4 (ArC), 121.3 (ArC), 113.0 (ArC), 111.5 (ArC),
.3 (CH2), 32.5 (CH3). Anal. Calcd for C16H14N2O: C, 76.78; H,
4; N, 11.19. Found: C, 77.64; H, 5.68; N, 11.24.
.3.27. 1-(1H-Indol-2-yl)-2-pyridin-3-ylethanol (18)49.
monium formate (845 mg, 13.4 mmol) and Pd black (surface
ea 40–60 m2/g, 38 mg, 0.36 mmol) were added to a stirred solu-
n of ketone 7a (203 mg, 0.86 mmol) in dry methanol (100 mL).
no signiﬁcant amount of alcohol 18 was detected by TLC after
h, more Pd black (163 mg, 1.54 mmol) was added. Three days
er, as TLC indicated complete consumption of starting material,
e reaction mixture was ﬁltered through Celite 545 and the ﬁlter
s extensively washed with methanol. Concentration under re-
ced pressure, dilution with a small volume of ethyl acetate
d precipitation with cyclohexane yielded the title product as
dark orange solid (183 mg, 89%), mp 144–151 C with decompo-
ion. LC–MS Rt 4.4 min (method 1); m/z [MH+] 239. 1H NMR d
.06 (1H, br s, indole-H1), 8.35–8.32 (2H, overlapped, 2 ArH),
6 (1H, d, J = 7.8 Hz, ArH), 7.39 (1H, d, J = 7.8 Hz, ArH), 7.30
H, d, J = 8.0 Hz, ArH), 7.23 (1H, dd, J = 7.8, 4.8 Hz, ArH), 6.98ease cite this article in press as: Dolušic´, E.; et al. Bioorg. Med. Chem. (2H, t, J = 7.4 Hz, ArH), 6.89 (1H, t, J = 7.4 Hz, ArH), 6.18 (1H, br s,
H), 5.59 (1H, br s, OH), 4.88 (1H, m, CHOH), 3.10 (1H, dd,
H = 13.7 Hz, 3JHH = 5.5 Hz, CH2), 3.01 (1H, dd, 2JHH = 13.7 Hz,
H = 7.9 Hz, CH2). 13C NMR d 151.0 (ArC), 147.7 (ArC), 143.1
rC), 137.3 (ArC), 136.5 (ArC), 134.8 (ArC), 128.2 (ArC), 123.7
rC), 121.0 (ArC), 120.2 (ArC), 119.2 (ArC), 111.7 (ArC), 98.4
rC), 74.3 (CHOH), 41.0 (CH2).
.3.28. 2-(2-Pyridin-3-ylethyl)-1H-indole (19)50. Prepared
cording to a literature procedure.51 A suspension of indole ke-
ne 7a (111 mg, 0.47 mmol), hydrazine hydrate (47 ll,
7 mmol) and potassium hydroxide pellets (130 mg, 2.32 mmol)
ethylene glycol (5 mL) was subjected to microwave heating at
5 C for 1 h (P 40W, p = 1–3 bar). The resulting clear dark or-
ge solution was partitioned between dichloromethane and satu-
ted aqueous ammonium chloride. The aqueous phase was
tracted twice with dichloromethane and the combined organic
ers were dried over MgSO4. Concentration of the ﬁltered solu-
n combined with the addition of cyclohexane yielded the title
oduct as an ochre solid (87 mg, 84%), mp 139–142 C. LC–MS Rt
min (method 1); m/z [MH+] 223. 1H NMR d 10.95 (1H, br s, in-
le-H1), 8.41 (1H, s, ArH), 8.35 (1H, d, J = 4.8 Hz, ArH), 7.61 (1H,
, J = 7.8, 1.6 Hz, ArH), 7.35 (1H, d, J = 7.8 Hz, ArH), 7.27–7.24
H, overlapped, 2 ArH), 6.95 (1H, t, J = 7.5 Hz, ArH), 6.88 (1H, t,
7.5 Hz, ArH), 6.09 (1H, s, ArH), 3.00 (4H, overlapped, 2 CH2).
NMR d 150.1 (ArC), 147.8 (ArC), 139.4 (ArC), 137.2 (ArC),
6.5 (ArC), 136.3 (ArC), 128.8 (ArC), 123.9 (ArC), 120.7 (ArC),
9.7 (ArC), 119.1 (ArC), 111.2 (ArC), 99.2 (ArC), 32.2 (CH2), 29.6
H2). Anal. Calcd for C15H14N2: C, 81.05; H, 6.35; N, 12.60. Found:
80.33; H, 6.13; N, 12.15.
.3.29. 1-(1H -Indol-2-yl)-2-(pyridin-3-yl)ethanone oxime
0). A suspension of ketone 7a (52 mg, 0.22 mmol), hydroxyl-
ine hydrochloride (17 mg, 0.24 mmol) and pyridine (20 ll,
5 mmol) in absolute ethanol (1 mL) was subjected to microwave
ating at 120 C for 30 min. The resulting clear yellow solution
s evaporated with silica and oxime 20 was puriﬁed by auto-
ated ﬂash chromatography to yield a white solid (13 mg, 24%),
p 187–192 C. LC–MS Rt 5.2 min (method 1); m/z [MH+] 252. 1H
R d 11.43 (1H, br s), 11.11 (1H, br s), 8.55 (1H, d, J = 1.8 Hz, ArH),
4 (1H, dd, J = 4.8, 1.6 Hz, ArH), 7.65 (1H, d, J = 7.8 Hz, ArH), 7.47
H, d, J = 8.0 Hz, ArH), 7.34 (1H, d, J = 8.2 Hz, ArH), 7.26 (1H, dd,
7.9, 4.8 Hz, ArH), 7.07 (1H, t, J = 7.6 Hz, ArH), 6.93 (1H, t,
7.6 Hz, ArH), 6.84 (1H, d, J = 2.1 Hz, ArH), 4.08 (2H, s, CH2). 13C
R d 150.3 (C), 149.5 (C), 147.9 (C), 137.7 (ArC), 136.5 (ArC),
4.2 (ArC), 134.0 (ArC), 128.1 (ArC), 124.1 (ArC), 123.2 (ArC),
0.9 (ArC), 119.7 (ArC), 112.2 (ArC), 103.7 (ArC), 28.8 (CH2).44
.3.30. 1H-Indole-2-carboxylic acid pyridin-3-ylamide (21). A
llow suspension of 1H-indole-2-carboxylic acid (482 mg,
5 mmol) in thionyl chloride (5 mL) was boiled for 15 min, dur-
g which time the mixture became a clear dark brown solution.
is was concentrated under reduced pressure and the solid resi-
e was evaporated three times with toluene. 3-Aminopyridine
06 mg, 3.22 mmol) and diisopropylethylamine (785 ll,
3 mmol) were dissolved in dry THF (2 mL) to give a clear yel-
ish solution which was cooled to 0 C. A solution of the above
-indole-2-carbonyl chloride residue in THF (3 mL) was added
refully to give a red-brown mixture. The ice/water bath was re-
oved after 5 min and the reaction mixture was stirred for a fur-
er 25 min and then partitioned between ethyl acetate and
ter. The aqueous layer is extracted twice with ethyl acetate
d the combined organic layers were washed with brine and
ied over MgSO4. Chromatographic puriﬁcation (the title product
ted with 50–60% ethyl acetate) afforded amide 21 as a yellow
lid (372 mg, 53%), decomposes without melting above 258 C.010), doi:10.1016/j.bmc.2010.12.032
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22 December 2010LC–MS Rt 5.1 min (method 1);m/z [MH+] 238. 1H NMR d 11.80 (1H
br s, indole-H1), 10.40 (1H, s, CONH), 8.95 (1H, d, J = 2.3 Hz, ArH
8.29 (1H, dd, J = 4.6, 1.2 Hz, ArH), 8.19 (1H, dd, J = 8.4, 1.6 H
ArH), 7.66 (1H, d, J = 8.0 Hz, ArH), 7.45–7.42 (2H, overlapped,
ArH), 7.38 (1H, dd, J = 8.3, 4.8 Hz, ArH), 7.21 (1H, t, J = 7.5 H
ArH), 7.05 (1H, t, J = 7.5 Hz, ArH). 13C NMR d 160.6 (CONH), 145.
(ArC), 142.2 (ArC), 137.5 (ArC), 136.2 (ArC), 131.5 (ArC), 127.
(ArC), 127.5 (ArC), 124.6 (ArC), 124.2 (ArC), 122.4 (ArC), 120.
(ArC), 113.0 (ArC), 104.9 (ArC). Anal. Calcd for C14H11N3O: C
70.87; H, 4.67; N, 17.71. Found: C, 70.66; H, 4.57; N, 17.76.
5.2. Biology
5.2.1. Protein expression and puriﬁcation of recombinant
human IDO
The coding region for human IDO (Ala2-Gly403) was cloned int
a derivative of plasmid pET9 (Novagen). The recombinant plasmid
pETIDO, encodes a histidine tag at the N-terminus of IDO. Bacteria
strain BL21 AI (Invitrogen) was used for overexpression of IDO an
transformed with the pETIDO plasmid. The transformed cells wer
grown on a rotary shaker at 37 C and 220 rpm to an OD600 of 1.2
in LB medium supplemented with 25 lg/mL kanamycin, 50 lg/m
L-tryptophan and 10 lM bovine hemin (Sigma). The culture wa
cooled in a water/ice bath and supplemented again with 50 lg
mL L-tryptophan and 10 lM bovine hemin. The expression of His
tagged IDO was induced by the addition of 1% (w/v) arabinose. In
duced cells were grown at 20 C and 60 rpm for 20 h. Cells (1
culture) were collected by centrifugation, resuspended in 40 m
of 25 mMMes, 150 mM KCl, 10 mM imidazole, and protease inhib
itors (complete EDTA free, Roche Applied Science) (pH 6.5), an
disrupted with a French press. The extract was clariﬁed by centr
fugation and ﬁltration on a 0.22 lm ﬁlter. The enzyme was puriﬁe
by IMAC using Ni2þ as a ligand and an IMAC HITRAP column (5 m
GE Healthcare). Brieﬂy, the extract was loaded on the column wit
25 mM Mes, 150 mM KCl, and 10 mM imidazole (pH 6.5). The co
umnwas washed with 50 mL of the same buffer with the imidazol
concentration adjusted to 100 mM. Finally, the protein was elute
with 25 mMMes, 150 mM KCl, and 50 mM EDTA (pH 6.5). The bu
fer was then exchanged into 25 mMMes and 150 mM KCl (pH 6.5
using a HITRAP desalting column (GE Healthcare). The purity of th
enzyme was estimated to be >95% based on the SDS–PAGE gel an
Coomassie blue staining. The ratio of absorbance at 404 nm to tha
at 280 nm of the protein was around 1.9.
5.2.2. Assay buffer
Assay buffer was composed of Phosphate Buffer 50 mM (p
6.5), Methylene Blue 5 lM (Sigma–Aldrich, M9140), and Ascorb
Acid 40 mM (Sigma–Aldrich, A5960). L-Tryptophan substrate (Sig-
ma–Aldrich, T0254) is diluted at 100 lM in Assay Buffer. IDO en-
zyme was diluted in Phosphate Buffer 50 mM at 0.05 mg/ml.
Hydrogen peroxide solution (Sigma–Aldrich, H1009) is prepared
at a concentration of 10 mM in water.
5.2.3. Enzymatic assay
Enzymatic Assay was performed in 384 Wells microplates (Gre-
iner bio one, 781108). Ninety ﬁve microliters of reaction buffer
with L-Tryptophan substrate at 100 lM and compound to be tested
are added in the microplate. The optical density at 320 nm of this
mixture is ﬁrst recorded as a baseline with a Spectramax plus spec-
trophotometer (Molecular Devices). The hIDO enzyme (0.375 lg in
5 ll) is then added to the mixture. After 60 min incubation at room
temperature, the reaction is stopped by the addition of hydrogen
peroxide (1 mM) and a second optical reading at 320 nm is per-
formed. The difference between the two density values reﬂects
the level of tryptophan degradation and is used to calculate the
percentage of IDO inhibition relative to the reference inhibitor
ll
Please cite this article in press as: Dolušic´, E.; et al. Bioorg. Med. Che1-MT. Dose–response inhibition of IDO is analyzed using GraphPa
Prism 4 program (GraphPad Software Inc.).
5.3. Cellular tests
5.3.1. Cell line
A plasmid construct encoding murine IDO was transfected int
mouse mastocytoma line P815B. Clone P185B-mIDO clone 6 (Uy
tenhove et al, 2003), which overexpresses IDO, was selected an
used for the cellular assay. Mouse IDO shares a 62% sequence iden
tity with human IDO, and the active site residues are 100
conserved.
5.3.2. Assay
The assay was performed in 96-well ﬂat bottom plates seede
with 2  105 cells in a ﬁnal volume of 200 ll. To determin
whether compounds were signiﬁcant IDO, the cells were incubate
overnight at 37 C in HBSS (Hanks Balanced Salt Solution, Invitro
gen) supplemented with 80 lM L-Tryptophan and 20 lM of th
compound. The plates were then centrifuged 10 min at 300
and 150 ll of the supernatant were collected. The supernatan
was analyzed by HPLC to measure the concentration of tryptopha
and kynurenine, based on the retention time and the UV absorp
tion (280 nm for tryptophan, 360 nm for kynurenine). For the HPL
analysis, 50 ll of supernatant were mixed with 500 ll acetonitril
to precipitate the proteins. After centrifugation, the supernatan
was collected, concentrated on a speedvac, resuspended in a ﬁna
volume of 100 ll water and injected in the HPLC (C18 column
In those conditions, about 50% of the initial amount of tryptopha
was degraded in the absence of inhibitor, and an equimola
amount of kynurenine was produced. The percentages of inhibitio
of tryptophan degradation and kynurenine production by the com
pounds were calculated in reference to this maximal activity. Th
initial wells containing the cells in the remaining volume of 50 l
were used to estimate cell viability in a classical MTT assay. To tha
end, 50 ll of culture medium (Iscove medium with 10% FCS an
amino acids) were added to the wells together with 50 ll o
MTT. After 3–4 h of incubation at 37 C, 100 ll of SDS/DMF wer
added to dissolve the crystals of formazan blue and the absorbanc
at 570/650 nm was measured after overnight incubation at 37 C
5.4. X-ray determination
X-ray measurements were performed on a Gemini Ultra R sys
tem (4-circle kappa platform, Ruby CCD detector) using MoK
radiation (k = 0.71073 Å) for the two compounds. After mountin
and centering of the single crystals on the diffractometer, ce
parameters were estimated from a pre-experiment run and fu
datasets collected at room temperature. Software for data reduc-
tion was CrysAliPro.52 Structures were solved by direct methods
1070from SHELXS-97 program53 and then reﬁned on F2 using SHELXL-97
software. Non-hydrogen atoms were anisotropically reﬁned and
the hydrogen atoms in the riding mode with isotropic temperature
factors ﬁxed at 1.2 times U (equiv) of the parent atoms.
CCDC 794450 and 794451 contain the supplementary crystallo-
graphic data for this paper and can be obtained free of charge via
www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cam-
bridge Crystallographic Data Centre, 12, Union Road, Cambridge
CB2 1EZ, UK; fax: +44 1223 336033; or deposit@ccdc.cam.ac.uk).
5.5. Molecular modeling
1080Molecular modeling studies were carried out on a Linux work-
station. The compounds were built using the SKETCH module
implemented in SYBYL (version 8.0).54 Docking was performed using
the 3D-coordinates of TDO (pdb code 2D0T) with the help of the
m. (2010), doi:10.1016/j.bmc.2010.12.032
automated GOLD program35 (active site deﬁnition: residues within
7 Å around PIM). In order to take protein ﬂexibility into account,
the enzyme-inhibitor complexes were optimized using the MINIMIZE
module. The minimization process uses the Powell method with
the Tripos force ﬁeld (dielectric constant 1r) to reach a ﬁnal con-
vergence of 0.01 kcal mol1.
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